TABLE 1.  Baseline monoamine metabolite levels in Alzheimer patients and controls a

Study

N

Group

Age

MHPG

HIAA

HVA

Units

Hartikainen et al. (29)

27

34

AD

NC

72.1 ± 7.5

49.3 ± 16.7

35.0 ± 7.5

33.8 ± 4.7

145 ± 44

135 ± 44

222 ± 77

209 ± 73

nmol/liter

Molchan et al. (44)

60

12

AD

NC

66.2 ± 8.7

65.8 ± 10.7

51.3 ± 16

51.1 ± 15

93 ± 31

95 ± 34

188 ± 74

202 ± 66

nmol/liter

 

Parnetti et al. (53)

15

30

14

AD

SDAT

NC

65.9 ± 2.5

79.8 ± 4.9

76.8 ± 8.8

46.0 ± 8.3

47.0 ± 8.7

47.3 ± 13.4

85 ± 30*

100 ± 30

101 ± 11

168 ± 51**

193 ± 80**

281 ± 42

nmol/liter

 

 

Tohgi et al. (72)

11

15

AD

NC

70.8 ± 8.2

69.1 ± 9.5

11.6 ± 4.1*

8.2 ± 2.3

29.3 ± 11.2

29.6 ± 11.0

29.5 ± 16.4

29.0 ± 17.4

ng/ml

 

Blennow et al. (10)

123

57

AD

NC

72.0 ± 7.2

72.2 ± 10.8

48 ± 14

50 ± 11

116 ± 49**

159 ± 63

203 ± 101

301 ± 121**

nmol/liter

Malm et al. (41)

14

21

AD

NC

71.2 ± 4.0

73.8 ± 8.2

36.3 ± 8.9

46.4 ± 33.4

153 ± 63

157 ± 191

247 ± 104

243 ± 102

nmol/liter

 

Kawakatsu et al. (35)

22

21

AD

NC

55.6

7.3 ± 2.5

6.3 ± 1.0

6.7 ± 3.5**

10.2 ± 2.5

15.8 ± 11.2

21.6 ± 5.6

ng/ml

 

Kaye et al. (35a))

 

27

14

AD

NC

69.4 ± 1.7

68.0 ± 2.9

40.3 ± 2.5

39.8 ± 3.4

113 ± 9.1

91 ± 13.7

161 ± 15

202 ± 27

nmol/liter†

 

Sunderland et al. (65)

13

 7

AD

NC

57.8 ± 5.1

61.6 ± 3.2

51.9 ± 4.5

54.3 ± 4.8

109 ± 10

109 ± 11

229 ± 22

228 ± 21

nmol/liter†

 

Raskind et al. (59)

       9 S

       7 M

       6

AD

AD

NC

68 ± 8

61 ± 6

67 ± 10

10.8 ± 1.8*

7.6 ± 1.0

7.6 ± 2.4

n/a

n/a

ng/ml

 

 

Palmer et al. (51)

21

38

AD

NC

69 ± 12

60 ± 6

8.3 ± 2.4

7.2 ± 2.3

15.3 ±  5.7*

21.4 ±  8.4

28.1 ± 13.4*

42.3 ± 17.1

ng/ml

 

   a Data expressed in means ± standard deviation except where noted in the units column (dagger denotes mean ± standard error).

* p < 0.05, ** p < 0.01 compared to control value; n/a, not available; S, severe; M, moderate; AD, Alzheimer’s disease; NC, normal control.

 

 

 

 

published 2000